Structured evidence table for Vitamin K1 Bone Turnover Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin K1 Bone Turnover Randomized Trial | Conclusion The data from this post-hoc analysis do not provide evidence for the assumption that vitamin K status modifies or enhances effects of vitamin D supplementation on cardiovascular or bone parameters. | 2 | Theiler-Schwetz V (2026) | Vitamin K status has no influence on the effect of vitamin D supplementation on bone turnover and cardiovascular markers: a randomized controlled trial. |
| Vitamin K1 Bone Turnover Randomized Trial | These findings are in line with current guidelines, which do not routinely recommend vitamin K and D co-treatment in patients with osteoporosis. | 2 | Theiler-Schwetz V (2026) | Vitamin K status has no influence on the effect of vitamin D supplementation on bone turnover and cardiovascular markers: a randomized controlled trial. |
| Vitamin K1 Bone Turnover Randomized Trial | Background/objectives Vitamin K and D co-treatment may have additive effects on bone and cardiovascular health and is frequently used as an over-the-counter supplement. | 2 | Theiler-Schwetz V (2026) | Vitamin K status has no influence on the effect of vitamin D supplementation on bone turnover and cardiovascular markers: a randomized controlled trial. |
| Vitamin K1 Bone Turnover Randomized Trial | The primary aim of this study was to assess whether the effect of vitamin D supplementation on bone turnover markers and cardiovascular parameters is modified according to vitamin K status at baseline (i.e., serum levels of vitamin K1, MK4 and MK7). | 2 | Theiler-Schwetz V (2026) | Vitamin K status has no influence on the effect of vitamin D supplementation on bone turnover and cardiovascular markers: a randomized controlled trial. |
| Vitamin K1 Bone Turnover Randomized Trial | Body weight was measured once a week, and the food efficiency ratio (FER) was calculated by dividing the increased body weight from day1 to the final day by the food intake amount during the experiment period. | 4 | Kim Misung (2013) | Vitamin K1 (phylloquinone) and K2 (menaquinone-4) supplementation improves bone formation in a high-fat diet-induced obese mice |
| Vitamin K1 Bone Turnover Randomized Trial | p Diet efficiency was lower in the HF group than that in the N group (<0.01), but no difference was found between the HF group and the HF-K1 and HF-K2 groups. | 4 | Kim Misung (2013) | Vitamin K1 (phylloquinone) and K2 (menaquinone-4) supplementation improves bone formation in a high-fat diet-induced obese mice |
| Vitamin K1 Bone Turnover Randomized Trial | There was 2.31 ± 0.31 ng/ml of the osteoclast inhibitor, OPG, in the HF group, 2.35 ± 0.12 ng/ml OPG in the HF-K1 group, and 2.90 ± 0.11 ng/ml OPG in the HF-K2 group, demonstrating that the OPG concentration was increased. | 4 | Kim Misung (2013) | Vitamin K1 (phylloquinone) and K2 (menaquinone-4) supplementation improves bone formation in a high-fat diet-induced obese mice |
| Vitamin K1 Bone Turnover Randomized Trial | 1 2 (,) 3 () 4 () 5 () 6 12 (–) In view of the recent increase in the aged population in Korea, emphasis has been placed on the prevention of and treatment for chronic diseases.Obesity has been studied as a factor that causes chronic diseases such as diabetes,osteoarthritis,hypertension, and cardiovascular disease,and thus, it requires management. | 4 | Kim Misung (2013) | Vitamin K1 (phylloquinone) and K2 (menaquinone-4) supplementation improves bone formation in a high-fat diet-induced obese mice |
Source documents